MarketScreener Homepage > News > Sectors > Healthcare

News : Sectors

ROYAL PHILIPS

Italian banks help European shares snap losing streak

ABBVIE

CFO Chase to retire by mid-year 2019

PFIZER

Australian watchdog's appeal against Pfizer ruling dismissed by court

06:48a	CSL : Initial Director's Interest Notice	PU
05:49a	FDA Extends Date On BMY's SBLA, Genmab Meets Phase 3 Goals, NCNA, LPTX On Watch	AQ
05:48a	RAMSAY HEALTH CARE : ASX Announcement - CARES Notification of dividend / distribution	PU
04:58a	MEDTRONIC : Founder Earl Bakken Passes Away at Age 94	AQ
04:51a	NEVRO 24 HOUR DEADLINE ALERT : Approximately 24 Hours Remain; ClaimsFiler Reminds Investors with Losses in Excess of $100,000 of Deadline in Class Action Lawsuit against Nevro Corp. - NVRO	BU
04:31a	INCYTE : Lilly And Incyte Update Safety Analysis Of OLUMIANT	AQ
04:13a	ONO PHARMACEUTICAL : Opdivo (nivolumab) in Combination with Yervoy (ipilimumab) Shows Promising Results in Patients with Advanced Form of Bladder Cancer (47.1KB)	PU
03:08a	DAIICHI SANKYO : Presents Updated Results of Trastuzumab Deruxtecan (DS-8201) in Patients with HER2 Expressing Advanced Colorectal Cancer at 2018 European Society for Medical Oncology (ESMO) Congress	PU
02:09a	NATIONAL MEDICAL CARE CO. : Announces Resignation and Appointment of a CEO	AQ
01:55a	MMJ PhytoTech Ltd Investor Presentation	AW
01:50a	MMJ PhytoTech Ltd MediPharm Labs Management Team Appointments	AW
01:46a	MMJ PHYTOTECH LTD (ASX : MMJ) MediPharm Labs Management Team Appointments	AQ
12:48a	ACR 2018 : Lilly Shares Updated Safety Analysis of OLUMIANT® (baricitinib) in Patients with Moderately-to-Severely Active Rheumatoid Arthritis	PU
10/21	Genmab Announces Positive Topline Results in Phase III CASSIOPEIA Study of Daratumumab in Front Line Multiple Myeloma	GL
10/21	MERCK AND : BiolineRX tanks on trial results	AQ

Find Out How MarketScreener Premium Can Help You.
The best opportunities. On all the markets. In a single subscription.

10:26a	SELVITA : Polish companies using ground-breaking treatment in fight against cancer	AQ
10:11a	NetScientific (NSCI); portfolio company receives $10m investment for 40% stake	AQ
10:01a	UNITED THERAPEUTICS : CollPlant and United Therapeutics Announce Global Licensing and Commercialization Agreement for 3D Bioprinting of Solid-Organ Scaffolds for Human Transplants	PR
10:01a	COLLPLANT : and United Therapeutics Announce Global Licensing and Commercialization Agreement for 3D Bioprinting of Solid-Organ Scaffolds for Human Transplants	PR
10:01a	AC Immune Announces Dr. Andreas Muhs, Chief Scientific Officer, to Take Medical Leave of Absence	GL
09:33a	ALMIRALL : LLC Launches New Name at Fall Clinical Dermatology Congress	PU
09:25a	ECKERT & ZIEGLER STRAHLEN- UND MEDIZINTECHNIK AG : Notification and public disclosure of transactions by persons	EQ
09:25a	ECKERT & ZIEGLER STRAHLEN- UND MEDIZINTECHNIK AG : Notification and public disclosure of transactions by persons	EQ
09:21a	BRISTOL MYERS SQUIBB : Opdivo (nivolumab) in Combination with Yervoy (ipilimumab) Demonstrates Durable Four-Year Survival Benefits in Patients with Advanced Melanoma	BU
09:20a	ECKERT & ZIEGLER STRAHLEN- UND MEDIZINTECHNIK AG : Notification and public disclosure of transactions by persons	EQ
09:20a	ECKERT & ZIEGLER STRAHLEN- UND MEDIZINTECHNIK AG : Notification and public disclosure of transactions by persons	EQ
09:16a	GENENTECH : ’s Tecentriq Plus Chemotherapy (Carboplatin and Abraxane) as an Initial Treatment Helped People With Advanced Non-Squamous Non-Small Cell Lung Cancer Live Significantly Longer Compared to Chemotherapy Alone	BU
09:16a	NOVARTIS : COMBI-AD study of Tafinlar® + Mekinist® continues to demonstrate relapse free survival benefit in patients with BRAF V600-mutant stage III melanoma	AQ
09:16a	BRISTOL MYERS SQUIBB : Opdivo (nivolumab) Plus Low-Dose Yervoy (ipilimumab) Demonstrates Durable Clinical Benefit in Previously Untreated Patients with MSI-H or dMMR Metastatic Colorectal Cancer	BU
09:15a	ECKERT & ZIEGLER STRAHLEN- UND MEDIZINTECHNIK AG : Notification and public disclosure of transactions by persons	EQ
09:01a	KAROLINSKA DEVELOPMENT : portfolio company OssDsign announces FDA clearance for Cranioplug	AQ
08:45a	ECKERT & ZIEGLER STRAHLEN- UND MEDIZINTECHNIK AG : Notification and public disclosure of transactions by persons	EQ
08:45a	ECKERT & ZIEGLER STRAHLEN- UND MEDIZINTECHNIK AG : Notification and public disclosure of transactions by persons	EQ
08:40a	ECKERT & ZIEGLER STRAHLEN- UND MEDIZINTECHNIK AG : Notification and public disclosure of transactions by persons	EQ
08:40a	ECKERT & ZIEGLER STRAHLEN- UND MEDIZINTECHNIK AG : Notification and public disclosure of transactions by persons	EQ
08:35a	ECKERT & ZIEGLER STRAHLEN- UND MEDIZINTECHNIK AG : Notification and public disclosure of transactions by persons	EQ
08:33a	OXURION : Extends Partnership with Retina Global in Support of Bolivian Diabetic Retinopathy (BOLDR) Project	PU
08:26a	HSI opens up 106 pts at 25,668; H-share up 51 pts at 10,273	AQ
08:23a	REDX PHARMA : ROCK2 inhibitors poster to be presented	PU
08:18a	SHIRE : Form 8.3 - Takeda Pharmaceutical Company Limited	PU
08:16a	WIDECELLS : CellPlan deal with Smart Cells	PU
08:16a	MICROPORT SCIENTIFIC : Experts from Pakistan Society of Interventional Cardiology Visit...	PU
08:16a	MICROPORT SCIENTIFIC : ® Orthopedics Holds First University of Hong Kong - Sh...	PU
08:16a	MICROPORT SCIENTIFIC : ® Takes Firehawk® to Encore Seoul 2018 in Korea	PU
08:16a	C4X DISCOVERY : PDMR Shareholding	PU
08:15a	ASTRAZENECA : to present new data demonstrating breadth of research portfolio in renal disease at ASN Kidney Week 2018	PU
08:15a	SHIRE : Form 8.3 - Shire Plc	PU
08:12a	ROYAL PHILIPS : Philips initiates share repurchase program for up to 5 million shares to cover its long-term incentive and employee stock purchase plans	PU
08:12a	HISAMITSU PHARMACEUTICAL : Notification of the commencement of the Phase II clinical study of HP-5070 in Japan (a transdermal drug for the treatment of primary local hyperhidrosis)	PU
08:12a	SYSMEX : Strengthening Our Global R&D Structure to Foster Early-Stage Innovation	PU
08:05a	AGENNIX AG I.L. : Preliminary announcement of the publication of quarterly reports and quarterly/interim statements	EQ
08:05a	AGENNIX AG I.L. : Preliminary announcement of the publication of financial reports according to Articles 114, 115, 117 of the WpHG [the German Securities Act]	EQ
08:03a	ORYZON GENOMICS : to present at upcoming international conferences	PU
08:02a	MEDISTIM : Final results from the REQUEST study presented at EACTS	AQ
08:01a	ASTRAZENECA : Lynparza shows 70% reduction in PFS ovarian cancer	AQ
08:01a	HERANTIS PHARMA OYJ : Manager's Transactions - Pekka Simula	AQ
07:43a	EPIGENOMICS : Centers for Medicare & Medicaid Services publish final rate of $192 for Epigenomics’ colorectal cancer screening blood test Epi proColon®	PU
07:35a	EPIGENOMICS AG : Centers for Medicare & Medicaid Services publish final rate of $192 for Epigenomics' colorectal cancer screening blood test Epi proColon(R)	EQ
07:31a	DBV TECHNOLOGIES : Announces Submission of Biologics License Application for Viaskin Peanut to the U.S. Food and Drug Administration	AQ
07:13a	TAKEDA PHARMACEUTICAL : Investigational Subcutaneous Vedolizumab Achieves and Maintains Clinical Remission and Mucosal Healing at Week 52 in Patients with Ulcerative Colitis	PU
07:08a	ROYAL PHILIPS : Philips' Third Quarter Results 2018	PU
07:08a	DOTTIKON ES : Considerably Lower Net Sales and Net Income	PU
07:05a	Kuros Biosciences obtains US patent covering a method for producing osteoinductive materials	TE
07:00a	ADDEX THERAPEUTICS : Selective mGlu2 PAM ADX71149 Included in Review Highlighting Promising Investigative Drugs for Epilepsy (Review Published in Epilepsia Journal)	AQ
06:48a	CSL : Final Director's Interest Notice	PU

The best opportunities.
All the markets. Each month. In one click.

Discover

10:29a	MERCK AND : `s STING agonist shows positive action in early-stage cancer study	AQ
10:29a	EXELIXIS : Announces Results from Two Analyses Evaluating Effect of PD-L1 Expression or Prior Treatment with Checkpoint Inhibitors on Efficacy of Cabozantinib in Patients with Advanced Renal Cell Carcinoma	AQ
10:29a	LABORATORY OF AMERICA : LabCorp, AstraZeneca subsidiary team up for precision medicine development	AQ
10:28a	PIRAMAL ENTERPRISES : denies loan defaults by real estate developers	AQ
10:26a	BRISTOL MYERS SQUIBB : Provides Update on the Ongoing Regulatory Review of Opdivo Plus Low-Dose Yervoy in First-Line Lung Cancer Patients with Tumor Mutational Burden 10 mut/Mb	AQ

1 2 3 4 5 6 7 8 9 10 Next

MOST READ NEWS

1	BOMBARDIER, INC. : Bombardier sues Mitsubishi jet programme over trade secrets
2	ELON MUSK SAYS FIRST TUNNEL IS ALMOST DONE, OPENS DECEMBER 10: tweet
3	RYANAIR HOLDINGS PLC : RYANAIR : forecasts end to union troubles by Christmas
4	ROYAL PHILIPS : ROYAL PHILIPS : Philips 3Q Net Profit Declined
5	AUSTRALIA AND NEW ZEALAND BANKING GR : Institutional investors turn their backs on Australian banks